Clinical Trial Update: A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating JNJ-42165279 for Autism Spectrum Disorder has completed and posted results in 2025, assessing efficacy, safety, and tolerability in a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• JNJ-42165279

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Autism Spectrum Disorder | Phase 2 | Status: COMPLETED | Results posted: 2025-04-23